Buddy Lyons
Long only, growth, growth at reasonable price, value

Impax Labs: Beyond The Hayward Debacle, High Reward, Manageable Risk

Impax Laboratories Inc. (NASDAQ:IPXL) is engaged in the development, manufacture and marketing of generic (72% of revenue) and branded pharmaceuticals (28%). Impax has 44 ANDAs at the FDA and is developing another 25 generic products. In the branded area, the company had licensed Zomig (migraines) from AstraZeneca (NYSE:AZN) in February 2012. It was a strategic move that brought the company significant revenue and enabled the company to build sales and infrastructure for the marketing of Rytary, a long-acting reformulation of levodopa (a dopamine precursor) for treating Parkinson's Disease, currently awaiting approval. Rytary would be an important incremental advance in the treatment of Parkinson's since it would have reduced the "on-off" periods of regular levodopa. Rytary is...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details